The Glutaminase Inhibitor CB-839 (Telaglenastat) Enhances the Antimelanoma Activity of T-Cell–Mediated Immunotherapies
Sruthy Varghese, Snigdha Pramanik, Leila J. Williams, Hannah R. Hodges, Courtney W. Hudgens, Grant M. Fischer, Catherine K. Luo, Barbara Knighton, Lin Tan, Philip L. Lorenzi, Andrew L. Mackinnon, Jennifer L. McQuade, Yared Hailemichael, Jason Roszik, Weiyi Peng and Y.N. Vashisht Gopal
Mol Cancer Ther, 2021;20(3):500–11
- DOI:
http://dx.doi.org/10.1158/1535-7163.MCT-20-0430